Guanhao Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 26.7185 million yuan, a decrease of 4.02%

Guanhao Biotech released its Q3 2025 report, with a revenue of 293 million yuan for the first three quarters, a year-on-year increase of 5.52%. The net profit attributable to the parent company was 26.7185 million yuan, a year-on-year decrease of 4.02%; the net profit excluding non-recurring gains and losses was 25.8206 million yuan, a year-on-year increase of 27.60%. The basic earnings per share were 0.1 yuan

Guanhao Biotech: Net profit of 20.4041 million yuan in the first half of 2025, a year-on-year increase of 1.27%

Guanhao Biotech announced that in the first half of 2025, operating revenue was 201 million yuan, a year-on-year increase of 5.89%. Net profit was 20.4041 million yuan, a year-on-year increase of 1.27%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

Biological vaccine stocks strengthened, among which, Shen Lian Biomedical rose over 10%, Global Printing 10CM hit the daily limit, Guanhao Biotech and Sinovac Biotech rose over 7%, Saili Medical rose over 5%, Kanglao Weishi, Jinhe Biotechnology, and Vland Biotech rose over 4%, Yongshun Biotech, Dezhan Health, Junzheng Group, and Kanghua Biotech rose over 3%

The concept of innovative drugs remains active, with Xintian Pharma and others hitting the daily limit

The concept of innovative drugs continues to be active, with Xintian Pharma, Fuyuan Pharmaceutical, CheezhengTTM, JLPC, and HSGC hitting the daily limit, Guanhao Biotech rising over 13%, and ALK increasing over 9%

The medical device sector saw a short-term surge, with JG Development hitting the daily limit

The medical device sector saw a short-term surge, with JG Development hitting the limit up, BIOLIGHT rising over 10%, and Improve Medical, Tianyi Medical, DIRUI, Guanhao Biotech, and Chunli Medical also following suit